证券日报网讯 9月22日晚间，一品红发布公告称，公司全资子公司广州一品红制药有限公司申报的馥感 啉颗粒（受理号：CXZL2500048）于近日获得国家药品监督管理局签发的药物临床试验批准通知书 （通知书编号：2025LP02464），同意本品开展用于成人气虚感冒的临床试验。 （文章来源：证券日报） ...

格隆汇9月22日丨一品红(300723.SZ)公布，全资子公司广州一品红制药有限公司（简称：一品红制药） 申报的馥感啉颗粒于近日获得国家药品监督管理局签发的药物临床试验批准通知书，同意本品开展用于 成人气虚感冒的临床试验。 ...

一品红（300723）(300723.SZ)公告，公司全资子公司广州一品红制药有限公司(简称：一品红制药)申报 的馥感啉颗粒于近日获得国家药品监督管理局签发的药物临床试验批准通知书，同意本品开展用于成人 气虚感冒的临床试验。 ...

Group 1 - The core point of the article is that Yipinhong Pharmaceutical's subsidiary has received approval for clinical trials of a new drug aimed at treating adult patients with Qi deficiency cold [1] Group 2 - Yipinhong Pharmaceutical's subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a clinical trial approval notice by the National Medical Products Administration [1] - The drug being tested is called Fuganling Granules, which is intended for use in adults suffering from Qi deficiency cold [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its drug, Fuganlin Granules, aimed at treating adult patients with Qi deficiency cold [1] Group 1 - The full subsidiary of the company, Guangzhou Yipin Hong Pharmaceutical Co., Ltd., is responsible for the drug's development [1] - The clinical trial approval notification number is 2025LP02464, indicating formal recognition by regulatory authorities [1] - The acceptance number for the drug application is CXZL2500048, which is part of the regulatory process [1]